Recruiting PHASE1 INTERVENTIONAL 2-arm NCT04778839

Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.

A Phase I Study of Dose Escalation and Dose Expansion To Evaluate the Safety、Tolerability、Pharmacokinetics and Efficacy of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumor.

Sponsor: First Affiliated Hospital of Zhejiang University

Conditions Advanced Solid Tumors

Interventions Paclitaxel Micelles for Injection Paclitaxel injection

Updated 6 times since 2021 Last updated: Aug 4, 2025 Started: Mar 4, 2021 Primary completion: Jun 30, 2026 Completion: Jun 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced Solid Tumors, this trial is actively recruiting participants. The trial is conducted by First Affiliated Hospital of Zhejiang University and has accumulated 6 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE1
Oct 2024 — Sep 2025 [monthly]

Recruiting PHASE1
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Mar 2023 — Jul 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Apr 2021 — Mar 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Mar 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

First Affiliated Hospital of Zhejiang University
Hangzhou Dihua Biotechnology Co., LTD.

Data source: First Affiliated Hospital of Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hanzhou, China